1.Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.
Meattini I1, Desideri I2, Di Cataldo V1, Francolini G2, De Luca Cardillo C1, Scotti V1, Loi M1, Detti B1, Mangoni M1,2, Agresti B1, Baldazzi V1, Greto D1, Casella D3, Bernini M3, Sanchez LJ3, Orzalesi L3, Nori J4, Fambrini M2, Bianchi S5, Livi L1,2. Future Oncol. 2016 May;12(9):1117-24. doi: 10.2217/fon-2015-0059. Epub 2016 Mar 9.
AIM: This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT.
2.Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.
Watanabe J1. Springerplus. 2015 Oct 19;4:625. doi: 10.1186/s40064-015-1422-8. eCollection 2015.
Despite being routinely prescribed worldwide for several years, data regarding the safety, efficacy, and survival benefit of eribulin in clinical settings for the treatment of metastatic breast cancer (MBC) are limited. This retrospective observational study investigated the survival benefit of eribulin compared with conventional chemotherapy regimens in Japanese women with MBC. Women with estrogen receptor (ER)-positive human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) MBC, including unresectable locally advanced breast cancer, treated at a single institution were included in this study. The primary efficacy measure assessed overall survival (OS), and safety was evaluated as the number of grade 3 and 4 adverse events. Of the 293 patients analyzed, 66 received eribulin (eribulin arm) and 227 received conventional chemotherapeutic agents excluding eribulin (noneribulin arm). The median OS from MBC diagnosis in the eribulin arm was 72.
3.Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials.
Ondo WG1, Hermanowicz N2, Borreguero DG3, Jaros MJ4, Kim R5, Shang G5. J Clin Mov Disord. 2015 Mar 30;2:9. doi: 10.1186/s40734-015-0018-3. eCollection 2015.
BACKGROUND: Dopamine agonists (DAs) are a first-line therapy for moderate-to-severe restless legs syndrome (RLS), but these treatments may lead to complications, such as augmentation and impulse control disorders, requiring switching to another therapeutic class. Here we assess efficacy and tolerability of gabapentin enacarbil (GEn) in adults with moderate-to-severe primary RLS, with or without prior DA exposure.
4.Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M1, De Maio E2, Guiu S3,4, Roca L5, Dalenc F6, Durigova A7,8, Pinguet F9, Bekhtari K10, Jacot W11, Pouderoux S12. BMC Cancer. 2015 Oct 8;15:659. doi: 10.1186/s12885-015-1673-3.
BACKGROUND: Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting.
